Table 1.
Size (mm3) of tumors before trastuzumab intervention.
| Days of observation | siHOTAIR-SK-BR-3-TR | SK-BR-3-TR | SK-BR-3-TS |
|---|---|---|---|
| 3 | 42.16 ± 5.26 | 40.28 ± 4.58 | 45.65 ± 4.85 |
| 6 | 282.35 ± 20.31 | 358.36 ± 14.25 | 302.68 ± 25.46 |
| 9 | 414.50 ± 18.57 | 626.66 ± 18.02 | 492.08 ± 26.31 |
| 12 | 764.94 ± 86.54 | 1137.64 ± 75.50 | 793.66 ± 78.04 |
| 14 | 851.55 ± 45.22 | 1365.87 ± 145.20 | 880.60 ± 25.50 |
| 21 | 759.25 ± 24.44 | 1556.21 ± 156.54 | 790.65 ± 18.60 |
| 28 | 625.20 ± 46.78 | 1794.08 ± 88.60 | 675.00 ± 54.32 |
| 35 | 576.31 ± 68.22 | 2088.60 ± 184.65 | 540.40 ± 92.63 |
| 42 | 462.55 ± 65.37 | 2230.20 ± 384.65 | 480.40 ± 102.63 |